CISENDO®
World's first non-invasive endometrial cancer screening, filling a clinical gap
CDO1/CELF4 dual-gene methylation test using non-invasive sampling to replace invasive biopsy — the world's first non-invasive endometrial cancer screening, filling a clinical gap.
Robust clinical data support
Based on multi-center registered clinical trials, sensitivity and specificity both reach industry-leading levels.
Who needs this test?
- Women with abnormal uterine bleeding
- Endometrial cancer screening for postmenopausal women
- Endometrial pathology risk assessment for perimenopausal women
- High-risk women scheduled for hysteroscopy
How is it applied clinically?
- Non-invasive early screening for endometrial cancer
- Pre-hysteroscopy risk stratification to reduce unnecessary invasive procedures
- Follow-up and monitoring for high-risk populations
- Women's health screening programs at health checkup centers
Why choose us
World's first non-invasive endometrial cancer methylation test
Global patents, CE certification, and Malaysia registration
Recommended by the Chinese Expert Consensus on Three-Tier Prevention Strategies for Endometrial Cancer
Recommended by the Expert Consensus on Clinical Application of Gene Methylation Screening for Endometrial Cancer
Endometrial Cancer Related Publications
Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimens
Journal: Frontiers in Medicine
Affiliation: Gansu Provincial Maternity and Child-care Hospital
DOI: 10.3389/fmed.2026.1690020
Diagnostic Accuracy and Concordance of Self-Collected Cervical CDO1 and CELF4 Methylation Testing Compared With Physician Sampling for Endometrial Cancer
Journal: JCO Precision Oncology
Affiliation: The Second Xiangya Hospital of Central South University
DOI: 10.1200/PO-25-01081
CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts
Journal: Gynecologic Oncology
Affiliation: Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University)
DOI: 10.1016/j.ygyno.2026.01.776
The endometrial cancer detection using non-invasive hypermethylation of CDO1 and CELF4 genes in women with postmenopausal bleeding in Northwest China
Journal: CytoJournal
Affiliation: Gansu Provincial Maternity and Child-care Hospital
DOI: 10.25259/Cytojournal_78_2023
DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding
Journal: International Journal of Gynecological Cancer
Affiliation: The Third Xiangya Hospital, Central South University
DOI: 10.1136/ijgc-2024-005723
Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimens
Journal: Frontiers in Medicine
Affiliation: Gansu Provincial Maternity and Child-care Hospital
DOI: 10.3389/fmed.2026.1690020
Diagnostic Accuracy and Concordance of Self-Collected Cervical CDO1 and CELF4 Methylation Testing Compared With Physician Sampling for Endometrial Cancer
Journal: JCO Precision Oncology
Affiliation: The Second Xiangya Hospital of Central South University
DOI: 10.1200/PO-25-01081
CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts
Journal: Gynecologic Oncology
Affiliation: Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University)
DOI: 10.1016/j.ygyno.2026.01.776
The endometrial cancer detection using non-invasive hypermethylation of CDO1 and CELF4 genes in women with postmenopausal bleeding in Northwest China
Journal: CytoJournal
Affiliation: Gansu Provincial Maternity and Child-care Hospital
DOI: 10.25259/Cytojournal_78_2023
DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding
Journal: International Journal of Gynecological Cancer
Affiliation: The Third Xiangya Hospital, Central South University
DOI: 10.1136/ijgc-2024-005723
